| NCT Number | NCT03474770 |
| Lead Sponsor | Supernus Pharmaceuticals, Inc. |
| Conditions | Focal Impaired Awareness Seizures |
| Enrollment | 16 participants |
| Start Date | 2018-04-10 |
| Primary Completion | 2026-12-30 (estimated) |
| Study Completion | 2026-12-30 (estimated) |
| Updated on ClinicalTrials.gov | 2022-08-30 |